Numerai GP LLC Invests $1.22 Million in Zoetis Inc. (NYSE:ZTS)

Numerai GP LLC bought a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 7,513 shares of the company's stock, valued at approximately $1,224,000.

Several other large investors also recently modified their holdings of the stock. Atlantic Edge Private Wealth Management LLC lifted its stake in Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 140 shares during the last quarter. Rakuten Securities Inc. raised its stake in shares of Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after buying an additional 166 shares during the period. Navigoe LLC purchased a new position in shares of Zoetis during the 4th quarter valued at $30,000. Murphy & Mullick Capital Management Corp bought a new position in shares of Zoetis during the 4th quarter worth $44,000. Finally, Asset Planning Inc bought a new position in shares of Zoetis during the 4th quarter worth $58,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ZTS shares. Morgan Stanley lowered their price objective on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Barclays boosted their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. Piper Sandler raised their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday. Stifel Nicolaus reduced their price objective on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Finally, StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $212.75.

Zoetis Price Performance

NYSE:ZTS traded up $2.68 during mid-day trading on Friday, hitting $163.03. 2,391,686 shares of the stock traded hands, compared to its average volume of 2,513,944. The business's 50-day moving average price is $156.46 and its 200 day moving average price is $165.43. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company has a market cap of $72.58 billion, a PE ratio of 29.80, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The firm had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.38 EPS. On average, analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. This represents a 2.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.